Challener Douglas, O'Horo John, Tande Aaron J
Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Antimicrob Steward Healthc Epidemiol. 2023 Jul 17;3(1):e126. doi: 10.1017/ash.2023.193. eCollection 2023.
Physician characteristics may be correlated with medical treatment decisions and patient outcomes. This study examined the correlations between characteristics of infectious disease (ID) physicians and the use of the restricted antimicrobial meropenem.
This was a retrospective cohort study following 27 attending ID physicians for 5 years at a large academic medical center.
All inpatient ID clinical encounters between 2013 and 2018 were assessed for physician and patient characteristics, including patient Charlson Comorbidity Index, patient sex, ID service seeing the patient, physician career stage, physician training location, and physician sex. Adjusted and unadjusted odds ratios were calculated for the receipt of meropenem on the same day as an ID clinical note.
Between 2013 and 2018, meropenem was administered on the same day as 9046 (11.1%) of 81,787 inpatient ID encounters. After adjustment for patient and practice-specific factors, physician career stage was associated with administration of meropenem. Patients seen by mid-career and late-career ID physicians were more likely to receive meropenem than those seen by early-career physicians (aOR 1.22 95% confidence interval [CI 1.13-1.31 and aOR 1.17 95% CI 1.10-1.25, respectively).
ID provider characteristics may help target future antimicrobial stewardship program interventions.
医生的特征可能与医疗决策和患者预后相关。本研究调查了传染病(ID)医生的特征与限制使用的抗菌药物美罗培南使用情况之间的相关性。
这是一项回顾性队列研究,在一家大型学术医疗中心对27位ID主治医生进行了为期5年的跟踪研究。
对2013年至2018年期间所有住院ID临床诊疗记录进行评估,以获取医生和患者的特征信息,包括患者查尔森合并症指数、患者性别、诊治患者的ID科室、医生职业阶段、医生培训地点以及医生性别。计算在ID临床记录当天使用美罗培南的调整和未调整比值比。
在2013年至2018年期间,在81787次住院ID诊疗中,有9046次(11.1%)在当天使用了美罗培南。在对患者和特定医疗因素进行调整后,医生职业阶段与美罗培南的使用相关。与早期职业医生诊治的患者相比,中年和晚期职业ID医生诊治患者使用美罗培南的可能性更高(调整后比值比分别为1.22,95%置信区间[CI]为1.13 - 1.31;以及调整后比值比为1.17,95% CI为1.10 - 1.25)。
ID医疗服务提供者的特征可能有助于确定未来抗菌药物管理计划的干预目标。